

1 **Unique combination of Recombinase Polymerase Amplification with label-free citrate-**
2 **stabilised silver nanoparticle assay offers a highly sensitive, fast, accurate and visual**
3 **molecular detection of *Klebsiella pneumoniae***

4

5 Naresh Patnaik^{a#}, Nidhi Orekonday^{a#}, Ruchi Jain Dey^{a,*}

6

7 ^aDepartment of Biological Sciences, BITS Pilani Hyderabad Campus, Telangana State –
8 500078, India

9

10

11 #Equal contribution as co-first authors

12 *Corresponding author

13 Email for correspondence: ruchij80@hyderabad.bits-pilani.ac.in

14

15

16 **Running Title:** Sensitive, fast, accurate and equipment-free molecular detection of
17 *Klebsiella pneumoniae*

18

19

20

21

22

23

24

25

26

27

28

29 **Abstract**

30 Our study addresses the growing concern posed by *Klebsiella pneumoniae*, a significant
31 pathogen acknowledged by the World Health Organization (WHO). This bacterium is
32 particularly alarming due to its association with antimicrobial resistance (AMR), impacting
33 immunologically vulnerable populations, especially in hospital settings, and playing a crucial
34 role in wound management. Moreover, this pathogen raises significant concerns in maternal
35 and child health, being correlated with adverse outcomes like pre-term birth, low birth weight,
36 and increased susceptibility to infections in new-borns, often resulting in morbidity and
37 mortality.

38 A major obstacle to the effective and timely management of *K. pneumoniae* infections is the
39 absence of rapid and cost-effective detection tools in resource-poor point-of-care (POC)
40 settings. This study introduces an innovative combination of three POC-compatible methods:
41 Insta DNA™ card-based sample collection and DNA extraction, Recombinase polymerase
42 amplification (RPA)-based isothermal amplification, and a silver nanoparticle (AgNP)
43 aggregation assay for visual detection. Together, these methods offer simple yet highly
44 sensitive, specific, and rapid visual detection of as few as ~1 bacterium of *K. pneumoniae*
45 within ~45 minutes. The synergy of these methods eliminates the need for sophisticated
46 equipment, making it highly suitable for field and resource-poor POC applications.

47

48

49

50 **Keywords:** *Klebsiella pneumoniae*, antimicrobial resistance (AMR), nosocomial infections,
51 maternal and child health, pre-term labour or birth, wound infections, Recombinase
52 polymerase amplification (RPA), Silver nanoparticle (AgNP), point-of-care (POC) detection

53

54

55 Introduction

56 The escalation of antimicrobial resistance (AMR) constitutes a significant global health
57 threat, particularly within the notorious ESKAPE group of pathogens. This acronym
58 encompasses six highly virulent and antibiotic-resistant bacterial pathogens: *Enterococcus*
59 *species (spp.)*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*,
60 *Pseudomonas aeruginosa*, and *Enterobacter spp.* The ESKAPE group of pathogens has
61 garnered its name owing to their characteristic ability to escape or circumvent the action of
62 antimicrobial agents¹. Within the ESKAPE group of pathogens, the World Health
63 Organization (WHO) recognizes *K. pneumoniae* as a significant pathogen of concern,
64 primarily due to its association with increasing AMR¹⁻³. *K. pneumoniae* is recognized as a
65 cause of nosocomial infection and can infect a variety of anatomical sites in the human body,
66 causing severe conditions such as necrotizing pneumonia, urinary tract infections (UTIs),
67 wound or surgical site infections, bloodstream infections, septicemia, meningitis, and
68 pyogenic liver abscesses, making it difficult to treat in healthcare settings⁴⁻⁶. Typically,
69 immune-competent individuals do not succumb to *Klebsiella* infections. However, instances
70 of *Klebsiella* infections are prevalent among patients undergoing treatment for other medical
71 conditions such as COVID-19⁷. Those particularly vulnerable or immune-compromised
72 including individual's dependent on medical devices such as ventilators (respiratory
73 machines) or intravenous catheters and those subjected to prolonged courses of specific
74 antibiotics are often at heightened risk of contracting *Klebsiella* infections⁸.

75 *Klebsiella* infections are also important in the context of maternal and child health. In
76 pregnant women, *Klebsiella* infections can contribute to complications such as
77 chorioamnionitis, thereby increasing the likelihood of pre-term labour/birth⁹. Infections during
78 pregnancy poses significant risk of vertical transmission to foetus or neonatal infections
79 during or following the birth, leading to increased infant mortality^{10, 11}. Hence, preventive
80 measures and early detection of *Klebsiella* is paramount for timely intervention and effective
81 management of these infections in maternal and child healthcare settings.

82 Early intervention facilitates prompt initiation of appropriate medical measures, reducing the
83 risk of severe complications and preventing transmission. Conventional methods for
84 detecting *K. pneumoniae*, such as culture-based and biochemical techniques, are time-
85 consuming and provide limited information on abundance and strain diversity within samples,
86 with uncertain sensitivity¹². The recent introduction of whole metagenomics sequencing
87 (WMS) in clinical diagnostics has significantly enhanced diagnostic reliability, particularly in

88 intricate situations such as tissue biopsies and body fluids^{12, 13}. WMS provides superior
89 capabilities compared to traditional culture methods, offering comprehensive insights into
90 antibiotic resistance profiles, virulence features, and evolutionary analysis of bacterial
91 strains^{12, 14}. Nevertheless, the exorbitant cost, time involvement and requirement of highly
92 skilled individuals to perform and analyse the results currently restricts its routine application
93 in diverse healthcare settings. In contrast, PCR-based assays, particularly real-time
94 quantitative PCR¹⁵, have shown 100% sensitivity and specificity, with a limit of detection of
95 1-10 bacteria (**Table 1**). However, the cost of detection is extremely high due to requirement
96 of fluorescent probes and quantitative PCR (qPCR) equipment. Subsequent developments
97 introduced isothermal amplification methods, including loop-mediated isothermal
98 amplification (LAMP)^{16, 17} and recombinase polymerase amplification (RPA)¹⁸⁻²¹ and multiple
99 cross displacement amplification (MCDA)²², for rapid *K. pneumoniae* detection without the
100 requirement of expensive thermal cyclers or qPCR. LAMP alone or in combination with
101 clustered regularly interspaced short palindromic repeats (CRISPR) and MCDA combined
102 with lateral flow strip (LFS) has demonstrated comparable sensitivity (1-20 bacteria)
103 compared to qPCR. These methods achieve detection within 60-90 minutes under isothermal
104 conditions (~60-65°C)^{16, 17, 22} (**Table 1**). In comparison, RPA provides further advantage of
105 rapid (15-30 min) isothermal amplification at lower temperatures (~37-42°C) permitting
106 quicker detection²³. RPA when combined with Lateral Flow Strip (LFS) system is capable of
107 detecting as low as 100-1000 bacteria, highlighting scope for improving the sensitivity of
108 detection post RPA-based DNA amplification^{18, 19}. A recent study highlights utility of tailor-
109 made plasmonic aptamer-gold nanoparticle (AuNP) assay for detection of *Klebsiella* without
110 the need of amplification, however, the sensitivity of this methods is ~3400 bacteria²⁴. Despite
111 the progress in molecular detection methods for *Klebsiella*, high cost associated with
112 fluorescent primer probes, aptamers, additional reagents like CRISPR, LFS and AuNP poses
113 accessibility challenges for low-income and resource-poor settings highlighting need for cost-
114 effective visual detection tools. Another hurdle in POC settings is safe methods of sample
115 collection, storage, transport and genomic DNA extraction for molecular detection. InstaDNA
116 card consists of a special type of filter paper impregnated with a proprietary formula
117 containing reagents that promote cell lysis and protein denaturation with subsequent release
118 of nucleic acids that are entrapped within the matrix of the card and stabilized at room
119 temperature, allowing long-term storage²⁵⁻²⁷. Originally applied to the perseveration of blood
120 samples for forensics tests, collection of materials for genotypic analysis of microorganisms,
121 plants, and molecular epidemiologic studies, the cards have also been used to store

122 gynaecologic and non-gynaecologic cytology specimens for various molecular analyses²⁸.
123 Many advantages have been described for Insta DNA card, including low-cost, simple
124 extraction protocols, easy transportation, minimal storage space and no special infrastructure
125 being required²⁸. However, there are no previous reports for application of InstaDNA cards
126 for *K. pneumoniae* detection.


127 This study combines three unique POC friendly methods (a) InstaDNA card, for easy
128 sample collection and DNA extraction (b) RPA-based thermal amplification in addition to PCR
129 (c) application of silver nanoparticle (AgNP) aggregation assay developed in our laboratory²⁹
130 for rapid, sensitive and visual molecular detection of *K. pneumoniae*. This unique combination
131 is particularly suitable for *K. pneumoniae* detection in resource-poor settings without the need
132 of costly thermal cycler and equipment like centrifuge or qPCRs. The integration of these
133 methods is anticipated to address the clinical needs to mitigate the impact of *Klebsiella*
134 infections.

135 **Results and Discussion**

136 **InstaDNA card-based sample collection and DNA extraction followed by PCR based** 137 **molecular identification of *K. pneumoniae***

138 We first optimized *K. pneumoniae* PCR, utilizing genomic DNA extracted using
139 standard kit-based method and 2 sets of primers (**Table 2**), one described previously³⁰ and
140 another newly designed in this study. Both the primer sets target *16s rRNA* gene, however
141 yield amplicons of two different sizes, ~658 bp (primer set 1) and ~250 bp (primer set 2),
142 respectively. In addition, these primers were found to be highly specific without any cross-
143 reactivity towards non-target organisms (**Figure 1 A and B**). However, both the primer sets
144 showed specificity towards *Enterobacter spp.* in addition to *K. pneumoniae* (**Figure 1 A and**
145 **B**), owing to the fact that both these organisms belong to the same family with a negligible
146 genomic difference in their *16S rRNA* region. AGE-based detection post-PCR amplification
147 showed a sensitivity of detection of ~33 bacteria (equivalent to ~200 fg of gDNA of *K.*
148 *pneumoniae*) (**Figure 2 A and B**).

149




150

151 **Figure 1. Primer specificity and cross-reactivity verification of primers utilized for**
152 **detection of *K. pneumoniae* by PCR-AGE.** Figures depict AGE-based verification of *K.*
153 *pneumoniae* specific PCR carried out using two different primer sets designed to target 16S
154 *rRNA* gene, A. Primer set 1 produce an amplicon of ~658 bp, and B. Primer set 2 produce
155 an amplicon of ~250 bp. The primer specificity was verified using genomic DNA derived from
156 human and various human pathogens as negative controls such as, *M. tuberculosis*, *M.*
157 *bovis*, *M. bovis BCG*, *N. gonorrhoeae*, *C. trachomatis*, *U. urealyticum*, and ESKAPE
158 pathogens.

159

Figure 2




160

161 **Figure 2. Sensitivity of *K. pneumoniae* PCR-AGE-based detection.** Figure depicts a
162 sensitivity of detection of ~200 fg of gDNA of *K. pneumoniae* (~33 bacteria) using PCR-AGE
163 employing A. Primer set 1 (658 bp amplicon), and B. Primer set 2 (250 bp). The labels on top
164 of the gel indicate amount of the genomic DNA used per PCR reaction & approximation of
165 the number of bacteria. The negative controls include- No template control (NTC) and a mix
166 of genomic DNAs obtained from human and human pathogens, such as, *M. tuberculosis*, *M.*
167 *bovis*, *M. bovis* BCG, *N. gonorrhoeae*, *C. trachomatis*, *U. urealyticum*, and ESKAPE
168 pathogens, except that of the test organism.

169

170 We next tested various genomic DNA isolation methods (boiling lysis, InstaDNA card and
171 Whatman filter paper No. 1), suitable for POC using primer set 1 against 16S *rRNA* gene of
172 *K. pneumoniae* (**Figure 3**). The InstaDNA card and Whatman filter paper No. 1 methods show
173 comparably identical efficiency in elution and amplification (Figure 3). Due to the advantages
174 of InstaDNA cards pertaining to their ease of sample collection, storage and logistics, we
175 selected InstaDNA card for subsequent analysis and determined their sensitivity of detection
176 for *K. pneumoniae*. The synergy of InstaDNA card followed by PCR-AGE shows a sensitivity
177 of ~330 bacterial cells of *K. pneumoniae* (**Figure 4**).


178



179

180 **Figure 3. Comparative analysis of various POC gDNA isolation techniques using PCR-**
181 **AGE-based detection.** Figure depicts the AGE-based detection of PCR performed on gDNA
182 isolated using different POC methodologies, namely, boiling lysis, InstaDNA card-based
183 isolation, and Whatman Paper No 1 assay. The PCR was verified using primer set 1 (~658
184 bp) specific to *16S rRNA* gene of *K. pneumoniae*. InstaDNA card-based DNA isolation and
185 Whatman Paper No 1 assay displayed comparable efficiency of DNA isolation. The labels on
186 top of the gel indicate amount of the genomic DNA used per PCR reaction and the negative
187 controls used for each technique.

188



189

190 **Figure 4. Sensitivity of *K. pneumoniae* detection using InstaDNA card-based DNA**
191 **isolation followed by PCR-AGE for detection.** Figure depicts the AGE-based detection of

192 PCR performed on various dilutions of bacterial sample blotted onto InstaDNA card disc,
193 without elution step, and using primer set 2 (~250 bp) specific to 16S rRNA gene of *K.*
194 *pneumoniae*. The assay shows a sensitivity of detection of ~2 pg of gDNA of *K. pneumoniae*
195 (~330 bacteria). The labels on top of the gel indicate amount of the genomic DNA used per
196 PCR reaction & approximation of the number of bacteria. The negative controls included a
197 No template control (NTC).


198

199 **Bridging flocculation assay and AgNP assay for molecular detection of *K. pneumoniae*** 200 **post-PCR amplification**

201 We next performed paramagnetic bead-based bridging flocculation assay following
202 PCR and determined the sensitivity of visual detection and compared with PCR-AGE. PCR
203 performed using both the primer sets (**mentioned in Table 2**) showed a comparable
204 detection sensitivity of ~33 bacteria (**Figure 5 A and B**), which is similar to PCR-AGE (**Figure**
205 **2 A and B**).

206 For further enhancing the sensitivity of visual detection, we performed AgNP assay on
207 DNA obtained from PCR. The AgNP-based assay showed a 10-fold higher sensitivity of
208 detection (~3 bacteria, equivalent to ~20 fg of gDNA of *K. pneumoniae*) compared to PCR-
209 AGE and bridging flocculation (**Figure 6 A and B**). Hence, post-PCR amplification, silver
210 nanoparticle assay, exhibits a higher sensitivity of detection as compared to flocculation
211 assay and traditional AGE-based detection.


212



213

214 **Figure 5. Sensitivity of *K. pneumoniae* detection by PCR and paramagnetic bead-based**
215 **bridging flocculation assay.** Paramagnetic bead-based bridging flocculation assay was

216 performed on PCR products obtained using 16S rRNA gene-specific primer set 1 and 2
217 yielding amplicon size of A. 658 bp and B. 250 bp, respectively. The assay displays a similar
218 detection sensitivity of 200 fg (~33 bacteria) using both the primer sets. Presence of PCR
219 amplified DNA results in a visual floc (bead aggregate), however, absence or very low amount
220 of amplified DNA result in dispersed state of magnetic beads (brown solution). The sensitivity
221 of PCR-AGE (**Figure 2**) and PCR-Bridging flocculation assays were found to be comparable.
222



223
224 **Figure 6. Sensitivity of detection of *K. pneumoniae* by PCR and AgNP assay.** AgNP
225 aggregation-based visual detection assay performed on PCR products obtained using 16S
226 rRNA gene specific primer set 1 and 2 producing amplicon of, A. 658 bp and B. 250 bp,
227 respectively. Both the primer sets display detection sensitivity of 20 fg of *K. pneumoniae*
228 genomic DNA (~3 bacteria). Presence of amplified DNA causes AgNPs to remain in
229 dispersed state indicated by yellow color solution, however, absence or very low amount of
230 amplified DNA results in aggregation of AgNPs in presence of the aggregating agent (NaCl),
231 indicated by grey color solution.

232


233

234 **RPA-based Isothermal amplification of *K. pneumoniae* 16S rRNA region followed by** 235 **in-tube detection using AgNP**

236 We next assessed if isothermal amplification techniques such as RPA can be used in
237 combination with AgNP assay for rapid molecular detection of *K. pneumoniae*. RPA performs
238 amplification in ambient conditions (25 - 42°C) and hence well suited for resource poor point-

239 of-care (POC) settings, where scope of costly equipment is rare. We performed the RPA
240 amplification of the target regions of *K. pneumoniae* at 37°C. Out of the two primer sets
241 designed for the molecular detection of *K. pneumoniae*, only primer set 2 was found suitable
242 for consistent amplification using RPA. RPA-AGE showed a dramatic 33-fold improvement in
243 sensitivity of detection (~1 bacterium) (**Figure 7 A**), compared to PCR-AGE (~33 bacteria)
244 (**Figure 2 B**). RPA-AgNP assay (**Figure 7 B**) also exhibited marked improvement in
245 sensitivity of detection to as low as 1 bacterium comparable to RPA-AGE (**Figure 7 A**) and
246 was also comparable to PCR-AgNP assay (**Figure 6 B**). We also tested paramagnetic bead-
247 based bridging flocculation-based visual detection in combination with RPA. While the beads
248 offer an easy method to clean up RPA amplified products, however, gives inconsistent results
249 when used for flocculation based visual detection, hence not utilized for detection purpose
250 (data not shown).
251

Figure 7



252
253 **Figure 7. Sensitivity of detection of *K. pneumoniae* by RPA-AGE and RPA-AgNP assay.**
254 Figure depicts, A. AGE-based and B. Ag-NP assay-based detection of DNA amplified using

255 RPA employing primer set 2 (amplicon size, ~250 bp). The labels on top of the gel indicate
256 amount of genomic DNA used per RPA reaction and the corresponding number of bacteria.
257 Isothermal RPA-AGE and RPA-AgNP assays show comparable detection sensitivity of ~10
258 fg of *K. pneumoniae* genomic DNA, equivalent to ~1 bacterium.

259

260 **Conclusion**

261 This study offers a highly sensitive, rapid method for molecular detection of an important
262 human pathogen *K. pneumoniae* employing a unique combination of Insta-DNA card-based
263 DNA extraction, isothermal DNA amplification using RPA and AgNP assay for visual
264 detection. The RPA technique for isothermal DNA amplification, distinguishes itself from PCR
265 by the virtue of its speed of operation (15-20 min) at a constant temperature range (~25 - 42
266 °C) compared to other isothermal techniques like LAMP and MCDA requiring more time (~30
267 – 60 min) and higher temperature (60 - 65 °C). AgNP-based assay reported by us previously
268 for differential molecular detection of *Mycobacterium tuberculosis* and *M. bovis*²⁹, offers
269 unique advantage of visual detection in a highly sensitive and cost-effective manner. The
270 synergy of RPA and the AgNP assay eliminates the need for expensive thermal cycling
271 equipment, centrifuges, electrophoresis equipment, gel documentation facilities, and real-
272 time qPCR machines, making RPA particularly suitable for field and POC applications.
273 Additionally, the primer sets designed in this study allow the application of the same primers
274 for both PCR and RPA-based assays. However, considerations during primer design include
275 a higher GC content ($\geq 50\%$), longer primer length (20-35 bp), and maintaining the amplicon
276 size between 200-500 bp. These primer sets are non-labelled, hence further keeping the cost
277 of detection under check. This study is also the first report for application of paramagnetic
278 bead-based bridging flocculation assay for highly sensitive visual detection of *K. pneumoniae*
279 subsequent to PCR based amplification. InstaDNA card further offer a safe and simple
280 method for sample collection, storage and transport and rapid DNA extraction without need
281 of any sophisticated equipment or DNA extraction kits in POC settings in a highly cost-
282 effective manner (< 1 \$). Moreover, the DNA isolated using this method, is compatible with
283 down-stream amplification methods, though slightly less sensitive (~10 fold).

284 For the application of RPA based molecular detection with AgNP assay, it is important
285 to include a clean-up process to eliminate the dense reagents like PEG and RPA enzymes
286 which interferes with AGE and AgNP assay. Our study utilizes a highly efficient, yet cost-
287 effective and equipment-free method based on paramagnetic beads for PCR and RPA

288 derived amplicon clean-up process. The total cost of molecular detection utilizing a
289 combination of three POC methods is <5 \$ for InstaDNA-RPA-AgNP in comparison to <3\$
290 for InstaDNA-PCR-AgNP (including the cost of paramagnetic beads used for clean-up)³¹. The
291 only limitation of the RPA components at present is the higher cost compared to the PCR
292 reagents, however, considering the suitability of RPA to POC settings, efforts to mass
293 produce these reagents at lower cost may help in increasing the application of this useful tool
294 in clinical settings and make it more robust and affordable compared to PCR/qPCR³¹.
295 Incorporation of such isothermal reactions can significantly enhance the efficiency of
296 diagnostic procedures, facilitating a streamlined and expedited process for the accurate and
297 timely recognition of important pathogens in POC healthcare settings.

298

299 **Materials and methods**

300

301 **Ethics Statement**

302 The study was performed as per the guidelines and approval of the Institutional Biosafety
303 Committee (BITS/IBSC/2019-1/7 and BITS/IBSC/2019-1/8) utilizing appropriate biosafety
304 level 2 measures.

305

306 **Reagents and bacterial strains**

307 All the reagents employed in this study were sourced from Himedia Laboratories Pvt.
308 Ltd., unless mentioned otherwise. The oligonucleotide primers utilized, as outlined in **Table**
309 **1**, were obtained from Sigma Aldrich. MagGenome supplied the paramagnetic beads, while
310 Sigma Aldrich provided the AgNP (20 nm size, stabilized in citrate buffer, 20 mg/ml). Taq
311 polymerase and its associated reagents were procured from Takara Clontech. Twist Amp
312 Liquid Basic RPA Kit was obtained from TwistDX™.

313 Cultures of *Enterococcus faecalis* (ATCC 29212), *S. aureus* (MTCC 96), *K.*
314 *pneumoniae* (MTCC 109), *A. baumannii* (MTCC 12889), *P. aeruginosa* (MTCC 424),
315 *Enterobacter spp.* (MTCC 7104) and *Neisseria gonorrhoeae* (ATCC 19424) were acquired
316 from the American type culture collection (ATCC, distributed by Himedia Laboratories Pvt.
317 Ltd.) or Microbial Type Culture Collection and Gene Bank (MTCC), maintained by Institute of
318 Microbial Technology (IMTECH), Chandigarh, India. The WHO BCG Danish 1331 vaccine
319 sub-strain was obtained from the National Institute for Biological Standards and Control
320 (NIBSC), UK.

321 **Sample Collection and DNA extraction**

322 Genomic DNA (gDNA) was extracted from pure bacterial cultures using a standard kit-based
323 method, specifically the DNEasy Blood and Tissue Kit (Qiagen), with minor adjustments to
324 the manufacturer's protocol. For cost-effective and rapid gDNA isolation, we employed
325 various protocols, including Boiling Lysis³², Whatman filter paper No. 1³³ and InstaDNA card
326 method²⁵⁻²⁷. The resulting gDNA was quantified using NanoDrop Microvolume
327 Spectrophotometers (Thermo Fisher Scientific) and utilized for amplification reactions with
328 species-specific primers.

329

330 In the Boiling Lysis method, bacterial cell-pellets were resuspended in an in-house
331 lysis buffer (1X TE, 0.05% Triton-X 100), boiled at 95°C for 30 minutes, and centrifuged at
332 12,000g for 10 minutes to obtain the genomic DNA-containing supernatant. For the Whatman
333 paper method, microbial cells were washed with 1X PBS, resuspended in an in-house
334 extraction buffer (2% w/v CTAB, 1.42 M NaCl, 20 mM EDTA, 100 mM Tris-HCl [pH 8.0], 1%
335 w/v polyvinylpyrrolidone [PVP 40]), and lysed. A 3 mm Whatman No.1 disc was incubated in
336 the cell lysate, washed, and directly transferred to the PCR reaction mix for amplification.
337 Alternatively, DNA was eluted by dipping the disc in elution buffer (1X TE), heated at 95°C
338 for 2 minutes, and quantified as described above. In the InstaDNA card method, a known
339 bacterial culture of colony forming units (CFU), e.g., $33 \times 10^4/2 \mu\text{L}$, was blotted onto a 3 mm
340 InstaDNA card disc, allowed to dry, washed, and transferred to the PCR reaction mix for
341 amplification. Alternatively, the disc was transferred to elution buffer for DNA elution by
342 heating at 95°C for 2 minutes. Similarly, 10-fold serially diluted bacterial samples were blotted
343 onto separate discs and processed accordingly.

344

345 **PCR and Agarose gel electrophoresis (PCR-AGE)-based detection**

346 Specific oligonucleotide primers targeting *K. pneumoniae* were custom-designed and are
347 detailed in **Table 2**. Two sets of primers (set 1 and set 2) were designed targeting *16s rRNA*
348 gene of *K. pneumoniae* to achieve an amplicon size of ~658 base pairs and ~250 base pairs,
349 respectively. Primer specificity was confirmed *in silico* through NCBI-BLAST analysis. PCR
350 amplification was carried out in a Veriti Thermal Cycler from Applied Biosystems, using Taq
351 Polymerase sourced from Takara Clontech, following the manufacturer's instructions with
352 minor adjustments. Each 50 μL PCR reaction was prepared with a 1 μM primer mix in the
353 reaction mixture, and thermal cycling included an initial denaturation step at 95°C for 10

354 minutes, followed by 35 cycles of PCR conditions outlined in **Table 2**. The process concluded
355 with a final extension at 72°C for 10 minutes.

356

357 In order to validate the primer specificity for *K. pneumoniae*, genomic DNA samples
358 from diverse organisms which could possibly cause respiratory infections or pneumoniae,
359 were utilized as negative control, such as *Mycobacterium tuberculosis* (*M. tb*),
360 *Mycobacterium bovis* (*M. bovis*), *M. bovis* BCG, *N. gonorrhoeae*, *Chlamydia trachomatis*,
361 *Ureaplasma urealyticum*, *E. faecalis*, *S. aureus*, *A. baumannii*, *P. aeruginosa*, *Enterobacter*
362 *spp* and human DNA. The verification of PCR products was performed through AGE and
363 DNA was visualized by ethidium bromide dye-based staining. For sensitivity determination or
364 limit of detection analysis of PCR-AGE, serial ten-fold dilutions of genomic DNA templates of
365 *K. pneumoniae* ranging from 10 nanograms, ng (1.6×10^6 bacteria) to 10 femtograms, fg (1
366 bacterium) were employed in PCR reactions.

367

368 **RPA-AGE-based molecular detection of *K. pneumoniae***

369 Isothermal nucleic acid amplification was performed for the pathogens using Twist Amp
370 Liquid Basic RPA Kit (TwistDX, TALQBAS01kit) as recommended by the manufacturer with
371 minor modifications. Briefly, all the reagents provided in the kit are mixed with defined quantity
372 of DNA, reaction is initiated by addition of magnesium acetate, followed by incubation at 37°C
373 for 15-20 minutes. The RPA products are immediately cleaned up using XpressPure PCR
374 Cleanup kit (MagGenome, MG20Pcr-50) or NucleoSpin gel and PCR clean-up kit (Macherey-
375 Nagel, 740609.250) to eliminate enzymes, highly dense PEG and buffer components which
376 are known to interfere with the agarose gel electrophoresis. Both the kits allow equivalent
377 performance in terms of quality of the isolated DNA, however, MagGenome kit allows faster
378 (20 minutes) purification using simple magnetic stand-based purification unlike other PCR
379 clean up kits needing centrifuge and ~60 min purification time. Henceforth, we utilized
380 instrument-free paramagnetic bead-based purification for our study. Similar to PCR-AGE
381 assay, we determined the sensitivity or limit of detection of the RPA-AGE using serial ten-
382 fold dilutions of genomic DNA templates (10 ng - 10 fg, equivalent to 1.6×10^6 bacteria – 1
383 bacterium of *K. pneumoniae*). DNA was visualized by ethidium bromide dye-based staining.

384

385

386

387 **Visual detection of amplified products using bridging flocculation assay and citrate-**
388 **stabilized AgNPs**

389 Bridging flocculation assay and AgNP-based visual detection assays were performed using
390 PCR amplified products as described by us previously²⁹. Briefly, paramagnetic beads work
391 with a principle that they adsorb the amplified DNA molecules and flocculate upon addition
392 of flocculation buffer (sodium acetate and tween 20 at an acidic pH) due to the formation of
393 DNA bridges connecting the paramagnetic beads. Hence, presence of DNA amplified product
394 is determined by floc formation. Absence of DNA or lesser amount of the amplified product
395 doesn't form visible floc as DNA bridges are not formed, as indicated by brown dispersion²⁹.
396 Similarly, AgNP assay was carried out as described by us previously²⁹, wherein presence of
397 DNA prevents the aggregation of AgNPs upon addition of aggregating agent, sodium chloride
398 (NaCl) causing sliver dispersion to maintain yellow colour. However, in absence of DNA,
399 addition of NaCl leads to AgNP aggregation causing grey coloration of the dispersion.

400 While PCR products were detected using AGE, bridging flocculation and AgNP assay,
401 RPA-amplified products were exclusively detected visually using AgNP assay given the
402 higher sensitivity of AgNP-based visual detection (~3 bacteria) of PCR amplified products
403 compared to bridging flocculation (~33 bacteria). Briefly, 10 µl of RPA reaction products were
404 made up to a volume of 50 µl using sterile water. Amplified products were then cleaned-up
405 using MagGenome PCR clean up kit as per the manufacturer's instructions. Finally, DNA was
406 eluted in 20 µl of elution buffer (10 mM Tris, 1mM EDTA, pH 8.0) followed by incubation with
407 50 µl of the citrate-stabilized AgNP dispersion at room temperature for ~1 minute. Following
408 this, 5 µl of aggregating reagent (5M NaCl) was added to the assay tubes. The onset of AgNP
409 aggregation is promptly revealed (in < 1 min) by a grey colour dispersion in tubes lacking
410 amplicons (negative controls with DNA from non-target organisms or no-template controls,
411 NTC). Conversely, in tubes with amplified DNA, the addition of NaCl prevents AgNP
412 aggregation, resulting in the retention of a yellow colour. The entire process of purification
413 and visual detection is completed within a time frame of 20-25 minutes. The sensitivity of
414 detection was assessed by executing AgNP aggregation-based assay using amplicons
415 derived from RPA conducted with varying amounts of genomic DNA sourced from *K.*
416 *pneumoniae*.

417 **Ancillary Information**

418

419 **Corresponding Author Information:** Ruchi Jain Dey- ruchij80@hyderabad.bits-pilani.ac.in

420 **Author Contribution:** NP, NO and RJD have conceived and designed the project. NP and
421 NO have equal contribution to the work. NP and NO carried out the studies and designed
422 figures and analysed the results. RJD received the funding. NP and RJD have written and
423 edited the manuscript. All the authors reviewed and edited the manuscript.

424 **Funding**

425 RJD is thankful to Birla Institute of Science and Technology (BITS) Pilani, Hyderabad
426 campus, India for their funding support through intramural funding under Research Initiation
427 Grant (RIG) and Centre for Human Disease Research (CHDR). RJD is thankful to Defence
428 Research and Development Organization (DRDO), India for supporting through research
429 grant (LSRB/81/48222/LSRB-367/BTB/2020). RJD is thankful to the overall infrastructure
430 support by Department of Biological Sciences, BITS Pilani Hyderabad. NP is thankful to
431 Indian Council of Medical Research (ICMR), Govt. of India for providing Senior Research
432 Fellowship (RBMH/FW/2019/13). NO is thankful to LSRB, DRDO and BITS Pilani Hyderabad
433 for fellowship.

434 **Acknowledgements**

435 We acknowledge Dr. Raghunand R Tirumalai, Centre for Cellular and Molecular Biology
436 (CCMB), Hyderabad, India for providing genomic DNA for *M. tuberculosis H37Rv*. Dr.
437 Bappaditya Dey, National Institute of Animal Biotechnology (NIAB), Hyderabad, India is
438 acknowledged for *M. bovis* genomic DNA. We are grateful to Dr. Benu Dhawan, Department
439 of Microbiology, All India Institute of Medical Sciences (AIIMS, New Delhi, India) for giving
440 genomic DNA from *Ureaplasma urealyticum*. We thank Dr. Karthika Rajeeve, Rajiv Gandhi
441 Centre for Biotechnology, Trivandrum, India for providing *Chlamydia trachomatis* (L2
442 Serovar) genomic DNA.

443 **Data availability statement**

444 All data that supports the findings of this study are available from corresponding author
445 upon reasonable request.

446 **Conflict of Interest Statement**

447 Authors declare no conflict of interest.

448

449 **Abbreviations**

450 *M. tb*, *Mycobacterium tuberculosis*; *M. bovis*, *Mycobacterium bovis*; POC, Point-of-care; ml,
451 Millilitre; μ l, microlitre; PCR, Polymerase Chain Reaction; DNA, Deoxyribonucleic acid;
452 qPCR, Quantitative PCR; NTC, no-template-control; NaAc, Sodium Acetate; AgNP, Silver
453 Nanoparticles; dsDNA, Double stranded DNA; Tris, Tris(hydroxymethyl)aminomethane;
454 EDTA, Ethylene diamine tetra-acetic acid; NaCl, Sodium Chloride; LAMP, Loop-mediated
455 Isothermal Amplification; RPA, Recombinase Polymerase Amplification; MCDA, Multiple
456 cross displacement amplification; BCG, Bacille Calmette-Geurin; WHO, World Health
457 Organisation.

458

459 **References**

- 460 (1) Ballén, V.; Gabasa, Y.; Ratia, C.; Ortega, R.; Tejero, M.; Soto, S. Antibiotic resistance and
461 virulence profiles of *Klebsiella pneumoniae* strains isolated from different clinical sources.
462 *Frontiers in Cellular and Infection Microbiology* **2021**, *11*, 738223.
- 463 (2) Paczosa, M. K.; Meccas, J. *Klebsiella pneumoniae*: going on the offense with a strong
464 defense. *Microbiology and molecular biology reviews* **2016**, *80* (3), 629-661.
- 465 (3) Riwu, K. H. P.; Effendi, M. H.; Rantam, F. A.; Khairullah, A. R.; Widodo, A. A review:
466 Virulence factors of *Klebsiella pneumoniae* as emerging infection on the food chain. *Veterinary*
467 *World* **2022**, *15* (9), 2172.
- 468 (4) Podschun, R.; Ullmann, U. *Klebsiella* spp. as nosocomial pathogens: epidemiology,
469 taxonomy, typing methods, and pathogenicity factors. *Clinical microbiology reviews* **1998**, *11*
470 (4), 589-603.
- 471 (5) Effah, C. Y.; Sun, T.; Liu, S.; Wu, Y. *Klebsiella pneumoniae*: an increasing threat to public
472 health. *Annals of clinical microbiology and antimicrobials* **2020**, *19* (1), 1-9.
- 473 (6) Navon-Venezia, S.; Kondratyeva, K.; Carattoli, A. *Klebsiella pneumoniae*: a major
474 worldwide source and shuttle for antibiotic resistance. *FEMS microbiology reviews* **2017**, *41*
475 (3), 252-275.
- 476 (7) Sreenath, K.; Batra, P.; Vinayaraj, E.; Bhatia, R.; SaiKiran, K.; Singh, V.; Singh, S.; Verma,
477 N.; Singh, U. B.; Mohan, A. Coinfections with other respiratory pathogens among patients
478 with COVID-19. *Microbiology spectrum* **2021**, *9* (1), e00163-00121.
- 479 (8) Murphy, C. N.; Clegg, S. *Klebsiella pneumoniae* and type 3 fimbriae: nosocomial infection,
480 regulation and biofilm formation. *Future microbiology* **2012**, *7* (8), 991-1002.
- 481 (9) Bonasoni, M. P.; Palicelli, A.; Dalla Dea, G.; Comitini, G.; Nardini, P.; Vizzini, L.; Russello,
482 G.; Bardaro, M.; Carretto, E. *Klebsiella pneumoniae* chorioamnionitis: an underrecognized
483 cause of preterm premature rupture of membranes in the second trimester. *Microorganisms*
484 **2021**, *9* (1), 96.
- 485 (10) Seliga-Siwecka, J. P.; Kornacka, M. K. Neonatal outcome of preterm infants born to
486 mothers with abnormal genital tract colonisation and chorioamnionitis: a cohort study. *Early*
487 *human development* **2013**, *89* (5), 271-275.
- 488 (11) Puri, K.; Taft, D. H.; Ambalavanan, N.; Schibler, K. R.; Morrow, A. L.; Kallapur, S. G.
489 Association of chorioamnionitis with aberrant neonatal gut colonization and adverse clinical
490 outcomes. *PloS one* **2016**, *11* (9), e0162734.
- 491 (12) Lindstedt, K.; Buczek, D.; Pedersen, T.; Hjerde, E.; Raffelsberger, N.; Suzuki, Y.; Brisse,
492 S.; Holt, K.; Samuelsen, Ø.; Sundsfjord, A. Detection of *Klebsiella pneumoniae* human gut

- 493 carriage: a comparison of culture, qPCR, and whole metagenomic sequencing methods. *Gut*
494 *microbes* **2022**, *14* (1), 2118500.
- 495 (13) Bowers, J. R.; Lemmer, D.; Sahl, J. W.; Pearson, T.; Driebe, E. M.; Wojack, B.; Saubolle,
496 M. A.; Engelthaler, D. M.; Keim, P. KlebSeq, a diagnostic tool for surveillance, detection, and
497 monitoring of *Klebsiella pneumoniae*. *Journal of clinical microbiology* **2016**, *54* (10), 2582-
498 2596.
- 499 (14) Chavda, K. D.; Chen, L.; Fouts, D. E.; Sutton, G.; Brinkac, L.; Jenkins, S. G.; Bonomo,
500 R. A.; Adams, M. D.; Kreiswirth, B. N. Comprehensive genome analysis of carbapenemase-
501 producing *Enterobacter* spp.: new insights into phylogeny, population structure, and
502 resistance mechanisms. *MBio* **2016**, *7* (6), 10.1128/mbio.02093-02016.
- 503 (15) Wang, L.; Gu, H.; Lu, X. A rapid low-cost real-time PCR for the detection of *Klebsiella*
504 pneumonia carbapenemase genes. *Annals of clinical microbiology and antimicrobials* **2012**,
505 *11* (1), 1-6.
- 506 (16) Nakano, R.; Nakano, A.; Ishii, Y.; Ubagai, T.; Kikuchi-Ueda, T.; Kikuchi, H.; Tansho-
507 Nagakawa, S.; Kamoshida, G.; Mu, X.; Ono, Y. Rapid detection of the *Klebsiella pneumoniae*
508 carbapenemase (KPC) gene by loop-mediated isothermal amplification (LAMP). *Journal of*
509 *Infection and Chemotherapy* **2015**, *21* (3), 202-206.
- 510 (17) Qiu, X.; Liu, X.; Ma, X.; Wang, R.; Chen, S.; Li, F.; Li, Z. One-pot isothermal LAMP-
511 CRISPR-based assay for *Klebsiella pneumoniae* detection. *Microbiology Spectrum* **2022**, *10*
512 (4), e01545-01522.
- 513 (18) Hemwaranon, P.; Srisrattakarn, A.; Lulitanond, A.; Tippayawat, P.; Tavichakorntrakool,
514 R.; Wonglakorn, L.; Daduang, J.; Chanawong, A. Recombinase Polymerase Amplification
515 Combined with Lateral Flow Strip for Rapid Detection of OXA-48-like Carbapenemase Genes
516 in Enterobacterales. *Antibiotics* **2022**, *11* (11), 1499.
- 517 (19) Li, N.; Wang, L.; Wang, F.; Chen, H.; Tao, S.; Zhu, Q.; Liu, L.; Liang, W.; Ma, F. Rapid
518 Detection of *Klebsiella pneumoniae* Carrying Virulence Gene *rmpA2* by Recombinase
519 Polymerase Amplification Combined With Lateral Flow Strips. *Frontiers in Cellular and*
520 *Infection Microbiology* **2022**, *12*, 877649.
- 521 (20) Raja, B.; Goux, H. J.; Marapadaga, A.; Rajagopalan, S.; Kourentzi, K.; Willson, R. C.
522 Development of a panel of recombinase polymerase amplification assays for detection of
523 common bacterial urinary tract infection pathogens. *Journal of applied microbiology* **2017**,
524 *123* (2), 544-555.

- 525 (21) Lapa, S.; Surzhikov, S.; Blagodatskikh, S.; Shershov, V.; Chudinov, A. Recombinase
526 Polymerase Amplification for Rapid Detection of Human Bacterial Pneumonia Pathogens.
527 *Molecular Biology* **2023**, *57* (3), 544-549.
- 528 (22) Niu, L.; Zhao, F.; Chen, J.; Nong, J.; Wang, C.; Wang, J.; Gao, N.; Zhu, X.; Wu, L.; Hu,
529 S. Isothermal amplification and rapid detection of *Klebsiella pneumoniae* based on the
530 multiple cross displacement amplification (MCDA) and gold nanoparticle lateral flow
531 biosensor (LFB). *Plos one* **2018**, *13* (10), e0204332.
- 532 (23) Daher, R. K.; Stewart, G.; Boissinot, M.; Bergeron, M. G. Recombinase polymerase
533 amplification for diagnostic applications. *Clinical chemistry* **2016**, *62* (7), 947-958.
- 534 (24) Ahmadi, S.; Kamaladini, H.; Haddadi, F.; Sharifmoghadam, M. R. Thiol-capped gold
535 nanoparticle biosensors for rapid and sensitive visual colorimetric detection of *Klebsiella*
536 *pneumoniae*. *Journal of Fluorescence* **2018**, *28*, 987-998.
- 537 (25) Alyethodi, R.; Singh, U.; Kumar, S.; Alex, R.; Sengar, G.; Raja, T.; Deb, R.; Prakash, B.
538 Designing, optimization, and validation of whole blood direct T-ARMS PCR for precise and
539 rapid genotyping of complex vertebral malformation in cattle. *BMC biotechnology* **2021**, *21*
540 (1), 36.
- 541 (26) Ismailova, C.; Golkocheva-Markova, E.; Tenev, T.; Krumova, S. THE USE OF DRIED
542 BLOOD SPOTS FOR MEASURING THE IMMUNITY AGAINST HBV: THE SIGNIFICANCE
543 OF ANTIBODY DILUTION. *PROBLEMS of Infectious and Parasitic Diseases* **2019**, *47* (1),
544 16-20.
- 545 (27) Krumova, S.; Golkocheva-Markova, E.; Angelova, S.; Voleva, S.; Pavlova, A.;
546 Georgieva, I.; Genova-Kalou, P. Dried blood spots as a clinical samples for laboratory
547 diagnosis and surveillance of vaccine-preventable diseases in Bulgaria. *Am. Sci. Res. J. Eng.*
548 *Technol. Sci. ASRJETS* **2019**, *51* (1), 183-191.
- 549 (28) da Cunha Santos, G. FTA cards for preservation of nucleic acids for molecular assays:
550 a review on the use of cytologic/tissue samples. *Archives of pathology & laboratory medicine*
551 **2018**, *142* (3), 308-312.
- 552 (29) Patnaik, N.; Dey, R. J. Label-Free Citrate-Stabilized Silver Nanoparticles-Based, Highly
553 Sensitive, Cost-Effective, and Rapid Visual Method for the Differential Detection of
554 *Mycobacterium tuberculosis* and *Mycobacterium bovis*. *ACS Infectious Diseases* **2023**.
- 555 (30) Aurna, S. T. Rapid identification of *Klebsiella pneumoniae* using PCR based method
556 targeting 16S rRNA gene. BRAC University, 2017.
- 557 (31) Minhas, N.; Gurav, Y. K.; Sambhare, S.; Potdar, V.; Choudhary, M. L.; Bhardwaj, S. D.;
558 Abraham, P. Cost-analysis of real time RT-PCR test performed for COVID-19 diagnosis at

559 India's national reference laboratory during the early stages of pandemic mitigation. *Plos one*
560 **2023**, *18* (1), e0277867.

561 (32) Dey, R. J.; Dey, B.; Zheng, Y.; Cheung, L. S.; Zhou, J.; Sayre, D.; Kumar, P.; Guo, H.;
562 Lamichhane, G.; Sintim, H. O. Inhibition of innate immune cytosolic surveillance by an M.
563 tuberculosis phosphodiesterase. *Nature chemical biology* **2017**, *13* (2), 210-217.

564 (33) Zou, Y.; Mason, M. G.; Wang, Y.; Wee, E.; Turni, C.; Blackall, P. J.; Trau, M.; Botella, J.
565 R. Nucleic acid purification from plants, animals and microbes in under 30 seconds. *PLoS*
566 *biology* **2017**, *15* (11), e2003916.

567 (34) Liu, Y.; Liu, C.; Zheng, W.; Zhang, X.; Yu, J.; Gao, Q.; Hou, Y.; Huang, X. PCR detection
568 of *Klebsiella pneumoniae* in infant formula based on 16S–23S internal transcribed spacer.
569 *International journal of food microbiology* **2008**, *125* (3), 230-235.

570 (35) Kurupati, P.; Chow, C.; Kumarasinghe, G.; Poh, C. L. Rapid detection of *Klebsiella*
571 *pneumoniae* from blood culture bottles by real-time PCR. *Journal of clinical microbiology*
572 **2004**, *42* (3), 1337-1340.

573

574

575

576 **List of Tables**

577

578 **Table 1. List of visual detection methodologies developed previously for the molecular**
 579 **detection of *K. pneumoniae*.**

Sl. No.	Method of Amplification	Method of Detection	Sensitivity	Time complexity of detection	Reference
1	PCR	AGE	1.2×10^2 bacteria	~4-5 hours	34
2	Real-time PCR	Fluorescence	1 bacterium	~2 hours	15
3	Real-time PCR	Fluorescence resonance energy transfer (FRET)	10 bacteria	~2 hours	35
4	PCR	Gold nanoparticles	16×10^1 bacteria (1pg gDNA)	~2 hours	24
5	LAMP	AGE	1 bacterium	~25 min (LAMP) + 1hour Agarose gel	16
6	LAMP	CRISPR-based detection	16×10^1 bacteria (1pg gDNA)	~ 60 min	17
7	MCDA	Gold nanoparticle-LFS	16 bacteria (100 fg gDNA)	~ 30 min (estimated, not reported)	22
8	RPA	LFS	10^3 bacteria	~15 min	18
9	RPA	LFS	16×10^3 bacteria (0.1 ng/ul)	~33 min	19
10	Real-time RPA	Fluorescence probes	100-1000 bacteria	~12 min	20
11	RPA	AGE	$10^2 - 10^3$ bacteria	~1 hour	21

580

581 **Table 2. Primers for molecular detection of *Klebsiella pneumoniae***


582

Primer	Target gene (Amplicon size)	Primer sequence (5' → 3')	PCR conditions**
Primer set 1 ³⁰	16S rRNA gene (658 bp)	(F) ATGTCGCAAGACCAGAGTGG (R) GCACAACCTCCAAATCGACA	95°C, 30 sec; 61°C, 30 sec; 72°C, 30 sec.
Primer set 2*	16S rRNA gene (250 bp)	(F) AGGCAGCAGTGGGGAATATTGCA (R) ACTTGACAGACCGCCTGCGT	95°C, 30 sec; 68°C, 30 sec; 72°C, 30 sec.
*Primers designed using PrimerQuest tool (Integrated DNA Technologies) in this study. **Annealing temperatures obtained using gradient PCR.			

583

584

585 For Table of Contents Use Only



586